Patients’ individual genomes may affect efficacy, safety of gene editing
Gene editing has begun to be tested in clinical trials, using CRISPR-Cas9 and other technologies to directly edit DNA inside people’s cells, and multiple trials are recruiting or in the planning stages. A new study led by Boston Children’s Hospital and the University of Montreal raises a note of caution, finding that person-to-person genetic differences may undercut the efficacy of the gene editing process or, in more rare cases, cause a potentially dangerous “off target” effect.
The study adds to evidence that gene editing may need to be adapted to each patient’s genome, to ensure there aren’t variants in DNA sequence in or near the gene being targeted that would throw off the technology. Findings appear this week in the Proceedings of the National Academy of Sciences Early Edition (December 11-15).
“Humans vary in their DNA sequences, and what is taken as the ‘normal’ DNA sequence for reference cannot account for all these differences,” says Stuart Orkin, MD, of Dana-Farber Boston Children’s Cancer and Blood Disorders Center and co-corresponding author on the study with Matthew Canver, an MD-PhD student at Harvard Medical School. “We recommend that common variation be taken into account in designing targeting systems for therapeutic editing, to maximize efficacy and minimize potential safety concerns.”
The study analyzed 7,444 previously published whole-genome sequences. Based on a list of about 30 disease-related DNA targets that researchers are interested in altering through gene editing, the researchers made a second list of nearly 3,000 guide RNAs (gRNAs). These are bits of genetic code that have been developed to direct CRISPR-Cas9 enzymes to the right editing location on or adjacent to the target, like the address on an envelope.
The team, led by Orkin, Canver and Samuel Lessard of the University of Montreal, then looked to see whether any of the 7,444 individuals carried DNA sequence variants (“letter changes” or insertions/deletions) in the areas the gRNAs are looking for.
“If there are genetic differences at the site that CRISPR reagents are targeting for therapy, you are at risk for decreased efficacy or treatment failure,” explains Canver, who conceived and led the study in Orkin’s Boston Children’s Hospital lab. “A difference in just a single base pair can cause a decrease in binding efficiency due to a mismatch with the guide RNA. Overall, this can cause a reduction in treatment efficacy.”
The team found that such occurrences in the genome are not uncommon; about 50 percent of the analyzed gRNAs had the potential to be affected by variants at their target sites. In a few cases, the team found genetic variants that cause DNA sequences in the genome to more closely match a gRNA that could potentially draw it to the wrong place — resulting in an edit of a gene or other DNA region that’s not meant to be targeted.
“In rare cases, there was the potential to create very potent ‘off-target’ sites – where CRISPR reagents could bind and cut where they’re not intended to,” says Canver. “If an off-target effect happens to be in, say, a tumor suppressor gene, that would be a big concern.”
Although the study looked at CRISPR-Cas9 gene editing, the researchers believe their findings extend to other gene-editing tools such as zinc-finger nucleases (ZFN) and TAL effector nucleases.
“The unifying theme is that all these technologies rely on identifying stretches of DNA bases very specifically,” says Canver. “So, a variant that affects the target sequence could reduce guide RNA binding. Variants can also lead to binding at new sites that could potentially cause harm. As these gene-editing therapies continue to develop and start to approach the clinic, it’s important to make sure each therapy is going to be tailored to the patient that’s going to be treated.”
The Latest on: Gene editing
[google_news title=”” keyword=”gene editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatmenton November 18, 2022 at 11:51 am
Changpeng Zhao, who suspects FTX of leaking information that endangered his children, had set in motion the events that sank FTX last week and wiped out all of his rival's wealth. Holiday sales are ...
- Insights on the Gene Editing Global Market to 2031 - Players Include Addgene, Allele Biotech, Bio-Rad and Takara Bioon November 18, 2022 at 4:31 am
Dublin, Nov. 18, 2022 (GLOBE NEWSWIRE) -- The "Gene Editing Market By Technology, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ...
- Gene-editing spinoff led by Mass General Brigham veteranson November 17, 2022 at 1:50 pm
Massachusetts General Hospital in Boston has spun off a gene-editing diagnostics company aiming to partner with pharma companies to create new therapies that use the technology. SeQure Dx emerged from ...
- Gene Deal Adds New Dimension to Biotech ETF SBIOon November 16, 2022 at 1:37 pm
Those on the lookout might consider the ALPS Medical Breakthroughs ETF (SBIO), a biotech ETF that may benefit from good news at its second-largest holding, Ionis Pharmaceuticals, Inc. (IONS). Ionis ...
- How researchers used CRISPR gene editing to send immune cells after canceron November 14, 2022 at 12:54 pm
Last week, researchers published the results of a clinical trial that used CRISPR gene editing to create a large population of cancer-targeting immune cells. The trial was short, and the reprogrammed ...
- This gene-editing company that went public last month could rally 20%, Jefferies sayson November 14, 2022 at 9:47 am
That's an improvement from base editing, which can only address 30%. Search-and-replace can do more gene conversions without off-target editing or breaking double-strands of DNA, which allows it ...
- Ionis teams with Metagenomi and dives into gene editingon November 14, 2022 at 5:46 am
The RNA drug developer is paying the richly-funded startup $80 million in a wide-ranging alliance that marks its first foray into DNA editing medicines.
- After blazing trails in RNA-targeted drugs, Ionis jumps into gene editingon November 14, 2022 at 3:28 am
On Monday, the company announced a partnership with Metagenomi to kickstart these efforts. Ionis will pay the Bay Area gene-editing startup $80 million upfront as the companies work together to ...
- Ionis partners with Metagenomi to add gene editing to its broad technology platformon November 14, 2022 at 3:06 am
Collaboration with a leader in gene editing systems is Ionis' latest move to expand and diversify its technology CRISPR-Cas gene editing is a natural extension of Ionis' innovative approach to ...
- UCL: New gene editing strategy could lead to treatments for people born with immune system diseaseson November 11, 2022 at 8:06 pm
Researchers say the study, published in Science Translational Medicine, could lead to new treatments for a rare disease of the white blood cells that normally help to control the immune system – known ...
via Google News and Bing News